Revenue
2020
2021
2022
2023
2024
2025
Schott Pharma AG & CO KGaA (1SXP)
Price€23.05Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | €986.2M | €957.1M | €898.6M | €821.1M | €648.7M | €584.2M |
| Gross profit | €332.5M | €322.6M | €316.5M | €296.4M | €226.2M | €196.0M |
| Gross margin | 33.71% | 33.71% | 35.22% | 36.10% | 34.87% | 33.55% |
| Research & development | €27.9M | €24.3M | €26.8M | €23.5M | — | — |
| Operating expenses | €131.6M | €130.0M | €124.1M | €132.1M | €112.2M | €103.3M |
| Operating income | €200.8M | €192.6M | €192.4M | €164.4M | €114.0M | €92.7M |
| Operating margin | 20.36% | 20.12% | 21.41% | 20.02% | 17.57% | 15.86% |
| EBITDA | €280.3M | €257.6M | €239.0M | €219.7M | — | — |
| EBITDA margin | 28.42% | 26.91% | 26.60% | 26.76% | — | — |
| Net income | €147.0M | €150.3M | €151.9M | €125.8M | €101.2M | €77.6M |
| Net profit margin | 14.90% | 15.71% | 16.91% | 15.33% | 15.60% | 13.29% |
| Basic EPSper basic share | €0.97 | €0.99 | €1.01 | €0.83 | €0.67 | €0.51 |
| Diluted EPSper diluted share | €0.97 | €0.99 | €1.01 | €0.83 | €0.67 | €0.51 |